Background Data monitoring is now an established part of good practice in clinical trials. Bayesian procedures for data-monitoring of treatment trials have been proposed and used, but sometimes without explicit consideration of utilities. A natural statistical framework for evidence-based medicine is a Bayesian approach to decision-making that incorporates an integrated summary of the available evidence and associated uncertainty with assessment of utilities.
Methods We explore this approach to data monitoring, explicitly addressing separately the individual, scientific and public health perspectives. The Data Monitoring Committee's decision can then be thought of as a weighted combination of these perspectives. These ideas are illustrated with a trial of treatments for oesophageal cancer.
Results For a Bayesian approach without explicit utilities we show that a utility structure is, in fact, implicit, and that it may be viewed as a weighted sum of the individual and scientific utilities.
Conclusions We argue that explicit consideration of utilities leads to decisionmaking that is more transparent, and lays foundations for data monitoring of more complex trials.
Get full access to this article
View all access options for this article.
References
1.
1. Ellenberg SS, Fleming T, DeMets DL. Data monitoring committees in clinical Trials. New York: Wiley and Sons, 2002.
2.
2. Freedman L, Anderson G, Kipnis V et al. Approaches to monitoring the results of long-term disease prevention trials: examples from the women's health initiative. Controlled Clinical Trials1996; 17: 509–525.
3.
3. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials. Journal of the Royal Statistical Society1994; 157: 357–416.
4.
4. Whitehead J. The design and analysis of sequential clinical trials, 2nd edn.New York: Wiley, 1997.
5.
5. Pocock SJ. Size of cancer clinical trials and stopping rules. British Journal of Cancer1978; 38: 757–766.
6.
6. Geller NL, Pocock SJ. Interim analyses in randomised clinical trials: ramifications and guidelines for practitioners. Biometrics1987; 43: 213–223.
7.
7. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics1979; 35: 549–556.
8.
8. Berry DA, Wolff MC, Sack D. Public health decision making: a sequential vaccine trial. In Bernardo JM, Dawid P, Smith AFM eds. Bayesian Statistics 4. Oxford: Oxford University Press, 1992: 79–96.
9.
9. Bellman R. Dynamic programming.Princeton NJ: Princeton University Press, 1957.
10.
10. Parmigiani G. Modeling in medical decision making. A Bayesian approach. Chichester: Wiley, 2002.
11.
11. Lewis RJ. Bayesian hypothesis testing: interim analysis of a clinical trial evaluating phenytoin for the phrophyl-axis of early-post traumatic seizures in children. In Berry DA, Stangl DK eds. Bayesian biostatistics. New York: Marcel Dekker, 1996: 279–296.
12.
12. Qian W, Brown PJ. Bayes sequential decision theory in clinical trials. In Bernardo JM, Dawid AP, Smith AFM eds. Bayesian Statistics 6. Oxford: Clarendon Press, 1999: 829–838.
13.
13. Carlin BP, Kadane JB, Gelfand AE. Approaches for optimal sequential decision analysis in clinical trials. Biometrics1998; 54: 964–975.
14.
14. Parmar MKB, Spiegelhalter DJ, Freedman LS. The CHART trials: Bayesian design and monitoring in practice. Statistics in Medicine1994; 13: 1297–1312.
15.
15. Fayers PM, Ashby D, Parmar MKB. Bayesian data monitoring in clinical trials. Statistics in Medicine1997; 16: 1413–1130.
16.
16. Lee PM. Bayesian statistics: an introduction, 3rd edn.London: Arnold, 2004.
17.
17. Ashby D, Smith AFM. Evidence based medicine as Bayesian decision-making. Statistics in Medicine2000; 19: 3291–3305.
18.
18. Tan SB, Smith AFM. Exploratory thoughts on clinical trials with utilities. Statistics in Medicine1998; 17: 2771–2291.
19.
19. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. The Lancet2002; 359: 1733–1733.
20.
20. Parmar MKB, Griffiths GO, Spiegelhalter DJ, Souhami RL, Altman DG, van der Scheuren E. Monitoring of large randomised clinical trials: a new approach with Bayesian methods. The Lancet2001; 358: 375–381.
21.
21. Tan SB, Chung YFA, Tai BC, Cheung YB, Machin D. Elicitation of prior distributions for a phase III randomised controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. Controlled Clinical Trials2003; 24: 110–121.
22.
22. Raiffa H, Schlaifer R. Applied statistical decision theory. Boston: Harvard University Press, 1961.
23.
23. Lindley DV. The choice of sample size. The Statistician1977; 46: 129–138.
24.
24. Spiegelhalter DJ, Smith AFM. Decision analysis and clinical decisions. In Bithell JF, Coppi R eds. Perspectives in medical statistics. London: Academic Press, 1981: 103–131.
25.
25. Simes RJ. Application of statistical decision theory to treatment choices: implications for the design and analysis of clinical trial. Statistics in Medicine1986; 5: 411–420.
26.
26. Simes RJ. Treatment selection for cancer patients: application of statistical decision theory to the treatment of advanced ovarian cancer. Journal of Chronic Diseases1985; 38: 171–186.
27.
27. Lenert LA, Cher DJ, Goldstein MK, Bergen MR, Garber A. The effect of search procedures on utility elicitations. Medical Decision Making1998; 18: 76–83.
